0001415889-24-004781.txt : 20240222
0001415889-24-004781.hdr.sgml : 20240222
20240222160525
ACCESSION NUMBER: 0001415889-24-004781
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240220
FILED AS OF DATE: 20240222
DATE AS OF CHANGE: 20240222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MANNING MARTHA E
CENTRAL INDEX KEY: 0001227894
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36576
FILM NUMBER: 24664664
MAIL ADDRESS:
STREET 1: 700 PENNSYLVANIA DR
CITY: EXTON
STATE: PA
ZIP: 19341
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MARINUS PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001267813
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500
STREET 2: 100 MATSONFORD RD
CITY: RADNOR
STATE: PA
ZIP: 19087
BUSINESS PHONE: 484-801-4670
MAIL ADDRESS:
STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500
STREET 2: 100 MATSONFORD RD
CITY: RADNOR
STATE: PA
ZIP: 19087
FORMER COMPANY:
FORMER CONFORMED NAME: MARINUS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20031022
4
1
form4-02222024_040201.xml
X0508
4
2024-02-20
0001267813
MARINUS PHARMACEUTICALS, INC.
MRNS
0001227894
MANNING MARTHA E
5 RADNOR CORPORATE CENTER, SUITE 500
100 MATSONFORD RD
RADNOR
PA
19087
false
true
false
false
SVP, GEN. COUNSEL & CORP. SEC.
0
Common Stock
2024-02-20
4
S
0
1894
9.57
D
52966
D
The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units.
The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.07 to $9.78, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
/s/ Debra A. Mohollen, Attorney-in-Fact
2024-02-22